Prior to co-founding Macoma in 2010, Andrew worked at Perry Capital, a multi-strategy, multi-billion dollar hedge fund headquartered in New York City.
While at Perry, Andrew was a member of a six-person illiquid special situations investment team, where he focused on a variety of private investments across industries.
Prior to working on illiquid investments, Andrew held primary responsibility for investing in healthcare products companies on Perry's long/short equities team including biotechnology, pharmaceuticals, specialty pharmaceuticals, medical technology and equipment.
engaged in strategies including long/short equities, merger arbitrage, credit and private equity.
Before joining Perry, Andrew was a member of the biotechnology team in the equity research division at Goldman Sachs.
At Goldman, he
worked for an Institutional Investor #2 ranked biotechnology team.
Prior to Goldman, Andrew worked in the healthcare investment banking group at Merrill Lynch.
executed over $27 billion of transactions while at Merrill Lynch
, including mergers & acquisitions, debt/equity financings, and IPOs.
Andrew earned a Bachelor of Science in Biochemistry from the University of Virginia, where he was an Echols Scholar and graduated Phi Beta Kappa.